Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1346-8138.2011.01301.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
BLEOMYCIN INDUCED FLAGELLATE DERMATITIS IN A PATIENT WITH NON-SEMINOMA GERM CELL TUMOUR WITH BILATERAL UNDESCENDED TESTES.
J Ayub Med Coll Abbottabad
January 2024
Lahore Medical and Dental College, Lahore-Pakistan.
Identifying prothrombin and bone sialoprotein as potential drug targets for idiopathic pulmonary fibrosis.
BMC Pulm Med
October 2024
Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, No.8 Gongren Tiyuchang South Road, Chaoyang District, Beijing, 100020, China.
Background: Idiopathic Pulmonary Fibrosis (IPF) is a fatal disease with scarce therapeutic alternatives, which imposes a significant economic burden on society. The identification of novel drug targets is thus critically essential. Plasma proteins with discernible causal evidence hold promise as viable drug targets for this condition.
View Article and Find Full Text PDFHuman hypofunctional variants promote pulmonary fibrosis in the bleomycin-induced mouse model and patients with systemic sclerosis via expansion of SPP1 monocytes-derived macrophages.
Ann Rheum Dis
September 2024
Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
Article Synopsis
- The study investigates a genetic variant (p.Arg90His) in the neutrophil cytosolic factor 1 gene related to systemic lupus erythematosus and its association with systemic sclerosis (SSc).
- Data from diverse cohorts indicate that the -H90 allele significantly increases the risk of developing diffuse cutaneous SSc and lung fibrosis in affected patients.
- Findings reveal that this variant enhances profibrotic responses in blood monocytes and macrophages, contributing to the severity of lung fibrosis, both in mouse models and human patients with SSc.
Carbon monoxide attenuates cellular senescence-mediated pulmonary fibrosis via modulating p53/PAI-1 pathway.
Eur J Pharmacol
October 2024
Engineering Technology Research Center for the Utilization of Functional Components of Organic Natural Products, Dalian University, Dalian, 116622, Liaoning, China; Chronic Disease Research Center, Medical College, Dalian University, Dalian, 116622, Liaoning, China. Electronic address:
Article Synopsis
- The study investigates the effects of carbon monoxide-releasing molecule 2 (CORM2) on idiopathic pulmonary fibrosis (IPF), a severe lung condition often requiring transplants, by aiming to understand how it can prevent lung fibrosis in a mouse model.
- CORM2 was found to improve lung function and reduce key fibrosis markers, such as TGF-β and PAI-1, while decreasing DNA damage and cellular aging signs in lung cells.
- Results suggest that CORM2 could be a potential therapeutic strategy for IPF by targeting cellular senescence and the p53/PAI-1 signaling pathway, providing a new avenue for treatment.
Use of Sotrovimab for COVID-19 in a Patient with International Germ Cell Consensus Classification Poor Prognosis Testicular Germ Cell Tumor.
Case Rep Oncol
September 2023
Department of Urology, Kanagawa Cancer Center, Yokohama, Japan.
A 35-year-old man was diagnosed with stage IIIC non-seminoma with paralysis of the lower half of his body due to 8th thoracic spine metastasis. The patient received bleomycin, etoposide, and cisplatin (BEP) therapy. On day 4 of the second course of BEP, the patient developed a fever and was diagnosed with coronavirus disease (COVID-19).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!